Open Orphan plc (LON:ORPH) the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services, has today announced that its London-based subsidiary hVIVO has commenced the testing of an anti-viral for treating COVID-19 on behalf of its client Nearmedic International Ltd.
hVIVO has initiated work on this contract with Nearmedic International Ltd, a specialist pharmaceutical, biotechnological and medical business headquartered in Moscow, to test using hVIVO’s virology expertise and laboratory capability an anti-viral drug with potential utility for treating SARS-CoV2 (COVID-19) infections. This drug has both potential anti-viral and anti-inflammatory activity and as such could reduce both virus infectivity and disease severity respectively.
hVIVO will be testing its utility against a panel of viruses to include influenza virus, “normal”, circulating betacoronavirus and ultimately SARS-CoV2 (COVID-19).
Cathal Friel, Executive Chairman of Open Orphan, commented:
“We are very happy to be assisting in the battle against Covid-19 and are delighted to be working with Nearmedic International Ltd. hVIVO is a world leading provider of services to global vaccine and antiviral development companiesand our scientists have considerable knowledge from previous anti-viral trials which gives us confidence in our testing. We look forward to updating the market on a regular basis in the weeks and months ahead.”
